BlackRock reports 7.7% stake in Ginkgo Bioworks
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A stock. BlackRock’s reporting business units collectively beneficially own 4,122,510 shares, representing 7.7% of the Class A shares outstanding. They hold sole voting power over 4,013,128 shares and sole dispositive power over 4,122,510 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client’s interest exceeds five percent of Ginkgo Bioworks’ outstanding common shares. The position is reported by BlackRock as a parent holding company through relevant subsidiaries identified in an exhibit, and the filing is signed by Managing Director Spencer Fleming.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
parent holding company financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Ginkgo Bioworks (DNA) does BlackRock report owning?
Do any single BlackRock clients own over 5% of Ginkgo Bioworks (DNA)?
Who signed the amended Ginkgo Bioworks (DNA) Schedule 13G for BlackRock?
What does the Ginkgo Bioworks (DNA) Schedule 13G/A say about BlackRock subsidiaries?
AI-generated analysis. How Rhea-AI works. Not financial advice.